37
Participants
Start Date
December 19, 2023
Primary Completion Date
March 31, 2026
Study Completion Date
March 31, 2026
Injectable coenzyme I
On the first day, we will treat patients with Tybo Sulsintilimab ® 200mg IV and Dalutin ® Bevacizumab 15mg/kg IV every 21 days. The first to third days were treated with injectable coenzyme I, 100mg/day IV, every 21 days as a cycle.
AnhuiI Provincial Hospital, Hefei
Anhui Provincial Hospital
OTHER_GOV